Ambrx Biopharma Cayman, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
10975 North Torrey Pines Road, La Jolla, CA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
Ambrx Biopharma Inc. (to 10/10/2023)

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 434M shares
Common Stock, Shares, Outstanding 432M shares +59.9%
Common Stock, Value, Issued 43K USD +59.3%
Weighted Average Number of Shares Outstanding, Basic 391M shares +44.8%
Weighted Average Number of Shares Outstanding, Diluted 391M shares +44.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.12M USD -13.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1.12M USD -13.5%
Research and Development Expense 14.4M USD -20.3%
General and Administrative Expense 5.9M USD +22.3%
Operating Income (Loss) -19.2M USD +33.4%
Nonoperating Income (Expense) 1.65M USD +2325%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.5M USD +39%
Income Tax Expense (Benefit) 305K USD +136%
Net Income (Loss) Attributable to Parent -17.8M USD +38.2%
Earnings Per Share, Basic -0.05 USD/shares +54.5%
Earnings Per Share, Diluted -0.05 USD/shares +54.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 228M USD +248%
Accounts Receivable, after Allowance for Credit Loss, Current 81K USD -94.5%
Other Assets, Current 981K USD -0.51%
Assets, Current 241M USD +99.5%
Property, Plant and Equipment, Net 3.2M USD +1.56%
Operating Lease, Right-of-Use Asset 10M USD -15.3%
Intangible Assets, Net (Excluding Goodwill) 24.9M USD -2.46%
Other Assets, Noncurrent 357K USD -23.4%
Assets 280M USD +54.8%
Accounts Payable, Current 6.36M USD +11.7%
Accrued Liabilities, Current 9.56M USD -38.7%
Liabilities, Current 18.2M USD -29.4%
Contract with Customer, Liability, Noncurrent 1.75M USD -58.8%
Deferred Income Tax Liabilities, Net 880K USD 0%
Operating Lease, Liability, Noncurrent 9.16M USD -18.6%
Liabilities 29.6M USD -24.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -953K USD +5.36%
Retained Earnings (Accumulated Deficit) -325M USD -22.5%
Stockholders' Equity Attributable to Parent 250M USD +76.5%
Liabilities and Equity 280M USD +54.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13M USD +49.5%
Net Cash Provided by (Used in) Financing Activities 77.2M USD
Net Cash Provided by (Used in) Investing Activities 29.6M USD
Common Stock, Shares Authorized 950M shares +90%
Common Stock, Shares, Issued 432M shares +59.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 93.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 229M USD +244%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Depreciation 200K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 9.22M USD +10%
Operating Lease, Liability, Current 1.85M USD +40.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Preferred Stock, Shares Issued 0 shares
Operating Lease, Payments 673K USD +227%
Additional Paid in Capital 576M USD +41.2%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 200K USD -50%
Share-based Payment Arrangement, Expense 2.89M USD +53.6%